期刊文献+

白细胞介素-1α和白细胞介素1受体拮抗剂与多发性硬化病的相关性研究 被引量:2

Study on the correlation between interleukin-1αand interleukin-1 receptor antagonist and multiple sclerosis
下载PDF
导出
摘要 目的探讨白细胞介素-1α(IL-1α)和白细胞介素1受体拮抗剂(IL-1Ra)水平与多发性硬化病之间的相关性。方法选取2018年2月至2020年6月我院收治的多发性硬化病患者130例为病例组,并选取同期体检的健康志愿者130例为对照组,对两组受检对象进行外周血和脑脊液的IL-1α、IL-1Ra水平检测,同时对病例组患者在治疗前,治疗7 d、14 d、28 d后分别采集外周血、脑脊液检测IL-1α、IL-1Ra水平。对比病例组中两个亚组治疗前、治疗28 d后的外周血和脑脊液中IL-1α、IL-1Ra水平,并与对照组进行对比。结果病例组患者的外周血、脑脊液中的IL-1α水平均高于对照组,且IL-1Ra水平均低于对照组,差异有统计学意义(P<0.05);病例组患者治疗7 d、14 d、28 d后的外周血、脑脊液中的IL-1α水平逐渐降低,IL-1Ra水平逐渐提高,差异有统计学意义(P<0.05);治疗28 d后根据病例组的治疗效果分成预后良好组和预后不良组,两组治疗前的各指标比较,差异无统计学意义(P>0.05);治疗28 d后,预后良好组的各指标与对照组比较,差异无统计学意义(P>0.05);预后不良组的外周血、脑脊液IL-1α水平则均高于对照组,且IL-1Ra水平均低于对照组,差异有统计学意义(P<0.05)。结论白细胞介素-1α和白细胞1受体拮抗剂与多发性硬化病之间存在显著相关性,外周血和脑脊液中IL-1α、IL-1Ra表达异常可能与MS发病及病情转归密切相关,可作为判断病情严重程度、治疗效果的重要指标。 Objective To explore the correlation between the levels of interleukin-1α(IL-1α)and interleukin-1 receptor antagonist(IL-1Ra)and multiple sclerosis.Methods A total of 130 patients with multiple sclerosis admitted to our hospital from February 2018 to June 2020 were selected as the case group,and 130 healthy volunteers who received physical examination during the same period were selected as the control group.The levels of IL-1αand IL-1Ra in peripheral blood and cerebrospinal fluid of the two groups were detected.At the same time,peripheral blood and cerebrospinal fluid of the case group were collected to detect the levels of IL-1αand IL-1Ra before treatment,at 7 days,14 days,and 28 days after treatment.The levels of IL-1αand IL-1Ra in peripheral blood and cerebrospinal fluid were compared before and 28 days after treatment between the good prognosis group and the poor prognosis group of the case group,and compared with the control group.Results The levels of IL-1αin peripheral blood and cerebrospinal fluid in the case group were higher than those in the control group,and the IL-1Ra levels in the case group were lower than those in the control group(P<0.05).After 7 d,14 d,and 28 d of treatment,the levels of IL-1αin peripheral blood and cerebrospinal fluid in the case group gradually decreased,and IL-1Ra levels gradually increased(P<0.05).Twenty-eight days after treatment,the patients were divided into the good prognosis group and the poor prognosis group according to the treatment effect of the case group.There was no statistically significant difference in indicators between the two groups before treatment(P>0.05).After 28 days of treatment,the indicators of the good prognosis group were not significantly different from the control group,without significant difference(P>0.05).The levels of IL-1αin peripheral blood and cerebrospinal fluid in the poor prognosis group were higher than those in the control group,and IL-1Ra level in the poor prognosis group was lower than that in the control group,with significant difference(P<0.05).Conclusion There is a significant correlation between interleukin-1αand leukocyte-1 receptor antagonist and multiple sclerosis.The abnormal expression of IL-1αand IL-1Ra in peripheral blood and cerebrospinal fluid may be closely related to the onset and outcome of MS,and can be used as an important indicator to judge the severity of the disease and the treatment effect.
作者 孙薇 SUN Wei(Department of Neurology,the Second Hospital of Chaoyang City in Liaoning Province,Chaoyang122000,China)
出处 《中国现代医生》 2021年第14期45-48,共4页 China Modern Doctor
关键词 IL-1Α IL-1Ra水平 多发性硬化病 预后转归 IL-1α IL-1Ra level Multiple sclerosis Prognostic outcome
  • 相关文献

参考文献14

二级参考文献138

  • 1周国钰,胡学强.多发性硬化与B细胞免疫[J].脑与神经疾病杂志,2006,14(2):154-156. 被引量:1
  • 2刘洪波,方树友,王玉萍,连亚军,滕军放,张博爱.多发性硬化患者血清及脑脊液中白细胞介素-10、-12的水平[J].中华神经科杂志,2006,39(12):843-844. 被引量:4
  • 3吕传真,李振新,张华,戚晓昆,臧敬五.中国多发性硬化及相关中枢神经系统脱髓鞘疾病的诊断和治疗专家共识(草案)[J].中华神经科杂志,2006,39(12):862-864. 被引量:55
  • 4Haas J,Hug A,Viehover A,et al.Reduced suppressive effect of CD4^+CD25^high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with mul-tiple sclerosis[J].Eur J Immunol,2005,35(11):3343-3352.
  • 5Beyersdorf N,Gaupp S,Balbach K,et al.Selective targeting of regulatory T cells with CD28 superagonists allows effective thera-py of experimental autoimmune encephalomyelitis[J].J Exp Med,2005,202(3):445-455.
  • 6Polman C,Reingold S,Edan G,et al.Diagnostic criteria for mul-tiple sclerosis:2005 revisions to the 2001 McDonald criteria[J].Ann Neurol,2005,58(6):840-846.
  • 7Kataoka H,Takahashi S,Takase K,et al.CD25+CD4+regulato-ry Tcells exert in vitro suppressive activity independent of CT-LA-4[J].Int Immunol,2005,17(4):421-427.
  • 8Jun SM,Dchoa-Rep6raz J,Zlotkowska D,et al.Bystander-medi-ated stimulation of proteolipid protein-specific regulatory T(Treg)cells confers protection against experimental autoimmune encephalomyelitis(EAE)via TGF-β[J].Journal of Neuroimmu-nology,2012,245(1-2):39-47.
  • 9Ma A,Xiong Z,Hu Yx,et al.Dysfunction of IL-10-producing type I regulatory T cells and CD4+CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys [J].International Immunopharmacology,2009,(9):599-608.
  • 10Putheti P,Soderstrom M,Link H,et al.Effect of glatiramer ace-tate(Copaxone)on CD4+ CD25high T regulatory cells and their IL-10 production in multiple sclerosis[J].Journal of Neuroimmu-nology,2003,144(1-2):125-131.

共引文献48

同被引文献24

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部